Gathagan Bryan K. 4

What Happened

• Bryan K. Gathagan, a director of Immucell Corp (ICCC), was granted a derivative award on 2025-04-16 giving him the right to acquire 10,000 shares (reported as 10,000 shares @ $0.00). The filing states the options were granted as director compensation; no cash was paid by the insider at the time of grant.

Key Details

• Transaction date: 2025-04-16; reported as a grant/award (code A).
• Price reported on Form 4: $0.00 (reflects a derivative grant, not a market purchase).
• Shares acquired: right to 10,000 shares (derivative).
• Shares owned after transaction: not specified in the Form 4 filing.
• Filing date: 2026-04-14 — the Form 4 was filed roughly 12 months after the transaction (late filing), which reduces the immediacy of the disclosure.
• Remarks: Issuer granted the options to compensate directors for board services. No vesting or exercise terms were detailed in the filing.

Context

• This is a compensation award (common for directors) rather than an open-market purchase or sale. It does not by itself signal a buy or sell decision by the insider; the award creates the potential to acquire shares later if exercised according to the option terms (which were not disclosed). Late filing means investors received the disclosure well after the grant date.